Injectable Drugs
SKU
MRR-742BD517FCA4
Region
Global
Publication Date
January 2024
Delivery
Immediate
2022
USD 514.99 billion
2030
USD 1,088.55 billion
2023
USD 563.30 billion
CAGR
9.80%
Injectable Drugs Market by Molecule Type (Large Molecule, Small Molecule), Drug Class (Blood Factors, Cytokines, Immunoglobulin), Injection Routes, Application - Global Forecast 2023-2030

[193 Pages Report] The Injectable Drugs Market size was estimated at USD 514.99 billion in 2022 and expected to reach USD 563.30 billion in 2023, at a CAGR 9.80% to reach USD 1,088.55 billion by 2030.

Injectable Drugs Market
To learn more about this report, request a free sample copy

The injectable drugs market comprises sales and distribution of medications and therapies that are administered through intravenous (IV), intramuscular (IM), or subcutaneous (SC) injection routes. The market caters to various drugs, including antibiotics, insulin, vaccines, and oncology treatments, that are integral in treating multiple diseases and medical conditions. Injectable drugs have diverse applications ranging from emergency care to routine administration of chronic disease medications. They are used in hospitals, clinics, and, increasingly, self-care settings due to advancements in auto-injection devices. Several factors, such as the rising burden of chronic diseases, the growing use of prefilled and self-injectable drugs, and the ongoing practice of steady drug delivery vehicles for cancer treatment, drive the development of the injectable drugs market. However, the market faces limitations and challenges, including high research and development costs, regulatory compliance costs, and complex manufacturing processes under stringent conditions. On the other hand, new opportunities are emerging due to rapid developments and approvals in injectable drugs and strategic alliances among manufacturers for injectable drugs. Moreover, improving drug delivery methods' safety, convenience, and efficacy can lead to increased patient compliance and better outcomes.

Injectable Drugs Market - Global Forecast 2023-2030
To learn more about this report, request a free sample copy
Drug Class: Increasing preference for cytokines injectable protein for cell signaling

Blood factors, essential for blood clotting, are injectable agents used to treat and prevent bleeding in individuals with hemophilia and other clotting disorders. They are derived either from human plasma or through recombinant technology. Hemophilia A and B are the most common disorders requiring these treatments. Cytokines are a broad category of injectable proteins critical in cell signaling within the immune system. They include interferons, interleukins, and colony-stimulating factors and are used in treating cancers and autoimmune conditions. Immunoglobulins are essential immune system components commonly used for various immunodeficiency syndromes and autoimmune diseases. These drugs provide necessary antibodies for the immune system to combat pathogens. Insulin is a peptide hormone vital for the regulation of blood glucose levels. It is primarily administered to individuals with diabetes when their body cannot produce sufficient insulin naturally. Monoclonal Antibodies (mAbs) are engineered molecules that imitate the immune system’s capacity to fight off harmful pathogens. These drugs have transformed treatment across a spectrum of conditions, including cancer, autoimmune diseases, and infectious diseases. Peptide hormones encompass a variety of injectable hormones other than insulin, such as growth hormone, glucagon-like peptide-1 (GLP-1) agonists for diabetes, and calcitonin. They play various roles, including regulating growth, glucose metabolism, and bone homeostasis.

Application: Growing application of injectable drugs for treating autoimmune diseases

Injectable drugs for autoimmune diseases treat various conditions, including rheumatoid arthritis, multiple sclerosis, and Crohn’s disease. Biologics, a subclass of injectable drugs, are often prescribed due to their targeted approach to modulating the immune system. The need-based preference for injectables stems from their quick onset of action and higher efficacy than oral medications. Injectable drugs for cardiovascular diseases aim to manage conditions such as heart failure, arrhythmia, and hypertension. These injections are often critical in emergency settings, providing rapid action where delayed treatment, such as anticoagulants or clotting factors, can be fatal. For infectious diseases, injectable drugs are crucial for antivirals, antibiotics, and antifungals, especially when high blood concentrations are required quickly, or oral administration is not feasible. They are critical in hospital settings for severe or resistant infections. Neurology injectables treat disorders, including Alzheimer’s, multiple sclerosis, and migraines. Monoclonal antibodies are significant in this segment for their ability to cross the blood-brain barrier. Oncology injectables include chemotherapy agents, hormonal therapies, and immunotherapies, essential for treating various cancers. The preference for injections comes from the need to achieve high local concentration and to bypass gastrointestinal absorption issues. Injectable drugs for pain management, such as opioids and nonsteroidal anti-inflammatory drugs (NSAIDs), are preferred in acute, chronic, and post-operative pain management for their speed and efficacy. In comparing the application segments for injectable drugs, it is apparent that each serves a distinct need in the healthcare sphere. Autoimmune diseases require long-term treatment regimens where injectables offer sustained relief. In contrast, cardiovascular injectable drugs are often emergency-related and demand rapid physiological responses. Infectious disease injectables must be broad-spectrum and rapidly acting to curb infections effectively. Neurology benefits from the targeted delivery achieved by injectables, a distinct advantage given the blood-brain barrier challenge. Injectable oncology drugs offer the benefit of targeted therapy with higher concentrations at the tumor site. Lastly, pain management with injectables provides immediate relief from acute and severe pain, which is often unattainable with oral medications.

Regional Insights

In the Americas, particularly in the United States and Canada, there is a high demand for injectable drugs due to the prevalence of diseases such as diabetes and cancer. Advanced healthcare infrastructure and high per capita healthcare expenditure drive the innovation and adoption of new injection technologies. Drug efficacy, safety profiles, and ease of use influence customer purchasing behavior in these markets. South America's market for injectable drugs is growing steadily due to improving healthcare facilities, increasing economic stability, and governmental support for healthcare reforms in countries such as Brazil, Argentina, and Chile. Europe represents a developing injectable drug market with well-established healthcare systems and favorable reimbursement policies. Eastern European countries are experiencing faster growth rates due to increased accessibility to advanced therapeutics. The Middle East, with countries such as Saudi Arabia and the UAE, shows a promising injectable drugs market due to rising healthcare infrastructure and increasing private sector investments. Africa, on the other hand, is progressively adopting injectable drug therapies but faces challenges related to affordability and access to medicine. The APAC region is emerging as the fastest-growing market for injectable drugs, driven by economic growth, expanding healthcare sectors, and increasing investments in biopharmaceutical research. Countries such as China, India, and Japan are at the forefront, with a high demand for both generic and innovative injectable drugs. In China, local manufacturing and foreign investment are extensive, catering to a vast domestic market. Japan is known for its technological advancements and invests heavily in pharmaceutical R&D, including next-generation injectable treatments. With a burgeoning pharmaceutical industry, India offers a large market for injectable drugs. Low-cost manufacturing and a growing middle class impact purchasing behaviors favorably toward more affordable injectable options.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Injectable Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Injectable Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments
  • Sun Pharma and Taro announce merger agreement

    Sun Pharmaceutical Industries Ltd. and Taro Pharmaceutical Industries Ltd. agreed upon a definitive merger, wherein Sun Pharma is expected to purchase the remaining outstanding shares of Taro for USD 43 per share in cash, totaling USD 347.73 million. This acquisition is going to result in Taro becoming a privately held subsidiary of Sun Pharma. [Published On: 2024-01-18]

  • Glenmark launched Biosimilar of Popular Anti-Diabetic Drug, Liraglutide, in India

    Glenmark Pharmaceuticals Ltd. announced the Indian market introduction of Lirafit, a cost-effective biosimilar to the widely used anti-diabetic drug Liraglutide. With this launch, Glenmark has ventured into the injectable anti-diabetic market, taking another significant stride in the diabetes therapy space. [Published On: 2024-01-03]

  • Bristol Myers' injectable form of Opdivo meets main goal in kidney cancer trial

    Bristol Myers Squibb announced a significant advancement in administering itsoncology medication, Opdivo, having successfully trialed a new injectable form that streamlines the treatment process for kidney cancer patients. This injectable version utilizes Halozyme Therapeutics' innovative technology to facilitate a subcutaneous delivery, potentially revolutionizing patient and physician treatment experiences. [Published On: 2023-10-19]

Key Company Profiles

The report delves into recent significant developments in the Injectable Drugs Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Baxter International Inc., Biogen Inc., Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Chiesi Farmaceutici S.p.A., Cipla Limited, Daiichi Sankyo Co., Ltd., Dr. Reddy’s Laboratories Ltd., Eagle Pharmaceuticals, Inc., Eli Lilly and Company, EVER Neuro Pharma GmbH, F. Hoffmann-La Roche Ltd., Ferring B.V., Fresenius Kabi AG, Gilead Sciences, Inc., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Merck & Co., Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Sanofi S.A., SCHOTT PHARMA AG & CO. KGAA, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Injectable Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Molecule Type
    • Large Molecule
    • Small Molecule
  • Drug Class
    • Blood Factors
    • Cytokines
    • Immunoglobulin
    • Insulin
    • Monoclonal Antibodies
    • Peptide Hormone
  • Injection Routes
    • Intramuscular
    • Intraocular
    • Intrathecal
    • Intravenous
    • Subcutaneous
  • Application
    • Autoimmune Diseases
    • Cardiovascular Diseases
    • Infectious Diseases
    • Neurology
    • Oncology
    • Pain

  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

The report offers valuable insights on the following aspects:

  1. Market Penetration: It presents comprehensive information on the market provided by key players.
  2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
  3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
  4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
  5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

  1. What is the market size and forecast of the Injectable Drugs Market?
  2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the Injectable Drugs Market?
  3. What are the technology trends and regulatory frameworks in the Injectable Drugs Market?
  4. What is the market share of the leading vendors in the Injectable Drugs Market?
  5. Which modes and strategic moves are suitable for entering the Injectable Drugs Market?

  1. Preface
    1. Objectives of the Study
    2. Market Segmentation & CoverageINJECTABLE DRUGS MARKET SEGMENTATION & COVERAGE
    3. Years Considered for the Study
    4. Currency & PricingUNITED STATES DOLLAR EXCHANGE RATE, 2018–2022
    5. Language
    6. Limitations
    7. Assumptions
    8. Stakeholders
  2. Research Methodology
    1. INJECTABLE DRUGS MARKET RESEARCH PROCESS
    2. Define: Research Objective
    3. Determine: Research Design
    4. Prepare: Research Instrument
    5. Collect: Data Source
    6. Analyze: Data Interpretation
    7. Formulate: Data Verification
    8. Publish: Research Report
    9. Repeat: Report Update
  3. Executive Summary
    1. INJECTABLE DRUGS MARKET SIZE, 2022 VS 2030
  4. Market Overview
    1. IntroductionINJECTABLE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)INJECTABLE DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
    2. Injectable Drugs Market, by RegionINJECTABLE DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)INJECTABLE DRUGS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)GLOBAL INJECTABLE DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  5. Market Insights
    1. Market DynamicsINJECTABLE DRUGS MARKET DYNAMICS
      1. Drivers
        1. Rising Burden of Chronic Diseases
        2. Growing Use of Prefilled and Self-Injectable Drugs
        3. Ongoing Practice of Controlled Drug Delivery Vehicles for Cancer Treatment
      2. Restraints
        1. Rise in Incidences of Product Recall
      3. Opportunities
        1. Rapid Developments and Approvals in Injectable Drugs
        2. Strategic Alliances Among Manufacturers for Injectable Drugs
      4. Challenges
        1. Complex Manufacturing Process and Shortages of Injectable Drugs
    2. Market Segmentation Analysis
      1. Drug Class: Increasing preference for cytokines injectable protein for cell signaling
      2. Application: Growing application of injectable drugs for treating autoimmune diseases
    3. Market Trend Analysis
    4. Cumulative Impact of COVID-19
    5. Cumulative Impact of Russia-Ukraine Conflict
    6. Cumulative Impact of High Inflation
    7. Porter’s Five Forces Analysis
      1. Threat of New Entrants
      2. Threat of Substitutes
      3. Bargaining Power of Customers
      4. Bargaining Power of Suppliers
      5. Industry Rivalry
    8. Value Chain & Critical Path Analysis
    9. Regulatory Framework
    10. Client Customization
  6. Injectable Drugs Market, by Molecule Type
    1. IntroductionINJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2022 VS 2030 (%)INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2022 VS 2023 VS 2030 (USD MILLION)INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)
    2. Large MoleculeINJECTABLE DRUGS MARKET SIZE, BY LARGE MOLECULE, BY , 2018-2030 (USD MILLION)
    3. Small MoleculeINJECTABLE DRUGS MARKET SIZE, BY SMALL MOLECULE, BY , 2018-2030 (USD MILLION)
  7. Injectable Drugs Market, by Drug Class
    1. IntroductionINJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
    2. Blood FactorsINJECTABLE DRUGS MARKET SIZE, BY BLOOD FACTORS, BY , 2018-2030 (USD MILLION)
    3. CytokinesINJECTABLE DRUGS MARKET SIZE, BY CYTOKINES, BY , 2018-2030 (USD MILLION)
    4. ImmunoglobulinINJECTABLE DRUGS MARKET SIZE, BY IMMUNOGLOBULIN, BY , 2018-2030 (USD MILLION)
    5. InsulinINJECTABLE DRUGS MARKET SIZE, BY INSULIN, BY , 2018-2030 (USD MILLION)
    6. Monoclonal AntibodiesINJECTABLE DRUGS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY , 2018-2030 (USD MILLION)
    7. Peptide HormoneINJECTABLE DRUGS MARKET SIZE, BY PEPTIDE HORMONE, BY , 2018-2030 (USD MILLION)
  8. Injectable Drugs Market, by Injection Routes
    1. IntroductionINJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2022 VS 2030 (%)INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2022 VS 2023 VS 2030 (USD MILLION)INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)
    2. IntramuscularINJECTABLE DRUGS MARKET SIZE, BY INTRAMUSCULAR, BY , 2018-2030 (USD MILLION)
    3. IntraocularINJECTABLE DRUGS MARKET SIZE, BY INTRAOCULAR, BY , 2018-2030 (USD MILLION)
    4. IntrathecalINJECTABLE DRUGS MARKET SIZE, BY INTRATHECAL, BY , 2018-2030 (USD MILLION)
    5. IntravenousINJECTABLE DRUGS MARKET SIZE, BY INTRAVENOUS, BY , 2018-2030 (USD MILLION)
    6. SubcutaneousINJECTABLE DRUGS MARKET SIZE, BY SUBCUTANEOUS, BY , 2018-2030 (USD MILLION)
  9. Injectable Drugs Market, by Application
    1. IntroductionINJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2022 VS 2030 (%)INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2022 VS 2023 VS 2030 (USD MILLION)INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    2. Autoimmune DiseasesINJECTABLE DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY , 2018-2030 (USD MILLION)
    3. Cardiovascular DiseasesINJECTABLE DRUGS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY , 2018-2030 (USD MILLION)
    4. Infectious DiseasesINJECTABLE DRUGS MARKET SIZE, BY INFECTIOUS DISEASES, BY , 2018-2030 (USD MILLION)
    5. NeurologyINJECTABLE DRUGS MARKET SIZE, BY NEUROLOGY, BY , 2018-2030 (USD MILLION)
    6. OncologyINJECTABLE DRUGS MARKET SIZE, BY ONCOLOGY, BY , 2018-2030 (USD MILLION)
    7. PainINJECTABLE DRUGS MARKET SIZE, BY PAIN, BY , 2018-2030 (USD MILLION)
  10. Americas Injectable Drugs Market
    1. Introduction
    2. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)AMERICAS INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)AMERICAS INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)AMERICAS INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    3. AMERICAS INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)AMERICAS INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)AMERICAS INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
    4. Argentina
    5. ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)ARGENTINA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    6. Brazil
    7. BRAZIL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)BRAZIL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)BRAZIL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)BRAZIL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    8. Canada
    9. CANADA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)CANADA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)CANADA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)CANADA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    10. Mexico
    11. MEXICO INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)MEXICO INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)MEXICO INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)MEXICO INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    12. United States
    13. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    14. UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY STATE, 2022 VS 2030 (%)UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)UNITED STATES INJECTABLE DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  11. Asia-Pacific Injectable Drugs Market
    1. Introduction
    2. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    3. ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)ASIA-PACIFIC INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
    4. Australia
    5. AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)AUSTRALIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    6. China
    7. CHINA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)CHINA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)CHINA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)CHINA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    8. India
    9. INDIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)INDIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)INDIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)INDIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    10. Indonesia
    11. INDONESIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)INDONESIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)INDONESIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)INDONESIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    12. Japan
    13. JAPAN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)JAPAN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)JAPAN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)JAPAN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    14. Malaysia
    15. MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)MALAYSIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    16. Philippines
    17. PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)PHILIPPINES INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    18. Singapore
    19. SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)SINGAPORE INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    20. South Korea
    21. SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)SOUTH KOREA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    22. Taiwan
    23. TAIWAN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)TAIWAN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)TAIWAN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)TAIWAN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    24. Thailand
    25. THAILAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)THAILAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)THAILAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)THAILAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    26. Vietnam
    27. VIETNAM INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)VIETNAM INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)VIETNAM INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)VIETNAM INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  12. Europe, Middle East & Africa Injectable Drugs Market
    1. Introduction
    2. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    3. EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)EUROPE, MIDDLE EAST & AFRICA INJECTABLE DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
    4. Denmark
    5. DENMARK INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)DENMARK INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)DENMARK INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)DENMARK INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    6. Egypt
    7. EGYPT INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)EGYPT INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)EGYPT INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)EGYPT INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    8. Finland
    9. FINLAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)FINLAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)FINLAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)FINLAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    10. France
    11. FRANCE INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)FRANCE INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)FRANCE INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)FRANCE INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    12. Germany
    13. GERMANY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)GERMANY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)GERMANY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)GERMANY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    14. Israel
    15. ISRAEL INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)ISRAEL INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)ISRAEL INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)ISRAEL INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    16. Italy
    17. ITALY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)ITALY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)ITALY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)ITALY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    18. Netherlands
    19. NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)NETHERLANDS INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    20. Nigeria
    21. NIGERIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)NIGERIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)NIGERIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)NIGERIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    22. Norway
    23. NORWAY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)NORWAY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)NORWAY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)NORWAY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    24. Poland
    25. POLAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)POLAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)POLAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)POLAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    26. Qatar
    27. QATAR INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)QATAR INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)QATAR INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)QATAR INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    28. Russia
    29. RUSSIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)RUSSIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)RUSSIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)RUSSIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    30. Saudi Arabia
    31. SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)SAUDI ARABIA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    32. South Africa
    33. SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)SOUTH AFRICA INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    34. Spain
    35. SPAIN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)SPAIN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)SPAIN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)SPAIN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    36. Sweden
    37. SWEDEN INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)SWEDEN INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)SWEDEN INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)SWEDEN INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    38. Switzerland
    39. SWITZERLAND INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)SWITZERLAND INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)SWITZERLAND INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)SWITZERLAND INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    40. Turkey
    41. TURKEY INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)TURKEY INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)TURKEY INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)TURKEY INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    42. United Arab Emirates
    43. UNITED ARAB EMIRATES INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)UNITED ARAB EMIRATES INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)UNITED ARAB EMIRATES INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)UNITED ARAB EMIRATES INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
    44. United Kingdom
    45. UNITED KINGDOM INJECTABLE DRUGS MARKET SIZE, BY MOLECULE TYPE, 2018-2030 (USD MILLION)UNITED KINGDOM INJECTABLE DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)UNITED KINGDOM INJECTABLE DRUGS MARKET SIZE, BY INJECTION ROUTES, 2018-2030 (USD MILLION)UNITED KINGDOM INJECTABLE DRUGS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  13. Competitive Landscape
    1. FPNV Positioning MatrixINJECTABLE DRUGS MARKET, FPNV POSITIONING MATRIX, 2022INJECTABLE DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
    2. Market Share Analysis, By Key PlayerINJECTABLE DRUGS MARKET SHARE, BY KEY PLAYER, 2022INJECTABLE DRUGS MARKET SHARE, BY KEY PLAYER, 2022
    3. Competitive Scenario Analysis, By Key Player
      1. Sun Pharma and Taro announce merger agreement
      2. Glenmark launched Biosimilar of Popular Anti-Diabetic Drug, Liraglutide, in India
      3. Bristol Myers' injectable form of Opdivo meets main goal in kidney cancer trial
  14. Competitive Portfolio
    1. Key Company Profiles
      1. Abbott Laboratories
      2. AbbVie Inc.
      3. Amgen Inc.
      4. AstraZeneca PLC
      5. Baxter International Inc.
      6. Biogen Inc.
      7. Boehringer Ingelheim International GmbH
      8. Bristol-Myers Squibb Company
      9. Chiesi Farmaceutici S.p.A.
      10. Cipla Limited
      11. Daiichi Sankyo Co., Ltd.
      12. Dr. Reddy’s Laboratories Ltd.
      13. Eagle Pharmaceuticals, Inc.
      14. Eli Lilly and Company
      15. EVER Neuro Pharma GmbH
      16. F. Hoffmann-La Roche Ltd.
      17. Ferring B.V.
      18. Fresenius Kabi AG
      19. Gilead Sciences, Inc.
      20. GlaxoSmithKline PLC
      21. Johnson & Johnson Services, Inc.
      22. Merck & Co., Inc.
      23. Novartis AG
      24. Novo Nordisk A/S
      25. Pfizer Inc.
      26. Sanofi S.A.
      27. SCHOTT PHARMA AG & CO. KGAA
      28. Sun Pharmaceutical Industries Ltd.
      29. Teva Pharmaceutical Industries Ltd.
      30. Viatris Inc.
    2. Key Product Portfolio
  1. Abbott Laboratories
  2. AbbVie Inc.
  3. Amgen Inc.
  4. AstraZeneca PLC
  5. Baxter International Inc.
  6. Biogen Inc.
  7. Boehringer Ingelheim International GmbH
  8. Bristol-Myers Squibb Company
  9. Chiesi Farmaceutici S.p.A.
  10. Cipla Limited
  11. Daiichi Sankyo Co., Ltd.
  12. Dr. Reddy’s Laboratories Ltd.
  13. Eagle Pharmaceuticals, Inc.
  14. Eli Lilly and Company
  15. EVER Neuro Pharma GmbH
  16. F. Hoffmann-La Roche Ltd.
  17. Ferring B.V.
  18. Fresenius Kabi AG
  19. Gilead Sciences, Inc.
  20. GlaxoSmithKline PLC
  21. Johnson & Johnson Services, Inc.
  22. Merck & Co., Inc.
  23. Novartis AG
  24. Novo Nordisk A/S
  25. Pfizer Inc.
  26. Sanofi S.A.
  27. SCHOTT PHARMA AG & CO. KGAA
  28. Sun Pharmaceutical Industries Ltd.
  29. Teva Pharmaceutical Industries Ltd.
  30. Viatris Inc.
GET A FREE SAMPLE
This FREE sample includes market data points, ranging from trend analysis to market estimates & forecasts. See for yourself.
Frequently Asked Questions about the Injectable Drugs Market
The Global Injectable Drugs Market size was estimated at USD 514.99 billion in 2022 and expected to reach USD 563.30 billion in 2023.
The Global Injectable Drugs Market to grow USD 1,088.55 billion by 2030, at a CAGR of 9.80%
Most reports are fulfilled immediately. In some cases, it could take up to 2 business days.
We will send you an email with login credentials to access the report. You will also be able to download the pdf and excel.
We are approaching our 7th anniversary in 2024!
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available and included in every purchase to help our customers find the research they need-when they need it.
Absolutely yes, with the purchase of additional user licenses.
Absolutely yes, so long as the 360iResearch cited correctly.